ClinicalTrials.gg
Active, not recruitingNCT04105231Updated Jan 27, 2026

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

A Phase 2 interventional study of Cannabidiol and Risperidone in Dual Diagnosis, sponsored by Lone Baandrup. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Lone Baandrup · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.

Planned enrollment
6th of 11
64 · median 64
Started
2021
the only one that year
Phase 2
6 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Lone Baandrup

Among the 11 studies testing cannabidiol in Psychotic Disorders, this one is the 6th largest by planned enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 7th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cannabidiol in Psychotic Disorders, or all of them as a file.
02

Study summary

This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.

Read the detailed description

People with psychosis and comorbid cannabis use are particularly difficult to treat because cannabis use worsens psychotic symptoms and increases the risk that a first-episode psychosis will progress to schizophrenia. It is the THC (tetrahydrocannabinol) content in cannabis that aggravates psychotic symptoms whereas the CBD content has potential therapeutic effects. This trial investigates treatment with CBD (without THC) versus risperidone (an antipsychotic agent) in people with psychosis and lifetime use of cannabis. We hypothesize that CBD will ameliorate psychotic symptoms and reduce the frequency of cannabis use to a larger extent than risperidone. Sleep disturbances are often a limiting factor in the treatment of psychosis, and it is also examined how CBD affects objective and subjective sleep quality as well as circadian rest-activity cycles. Based on previous studies investigating CBD as monotherapy in patients with schizophrenia, it is expected that CBD will be associated with fewer adverse events than risperidone.

03

Conditions studied

  • Dual Diagnosis

Browse trials for

Keywords

  • psychosis
  • cannabis
  • clinical trial
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ICD-10 diagnosis of schizophrenia (DF20.X), paranoid psychosis (DF22.X), acute/intermittent psychotic disorder (DF23.X), schizoaffective psychosis (DF25.X), other/not specified nonorganic psychotic disorder (DF28/DF29), or cannabis induced psychotic disorder (DF12.5)
  • PANSS ≥ 60 and score of ≥ 4 on ≥ 2 PANSS-Positive subscale items: Delusions (P1), conceptual disorganization (P2), hallucinatory behaviour (P3), grandiosity (P5), suspiciousness (P6)
  • Lifetime cannabis use
  • Age 18-45 years
  • Female patients of need to utilize a proper method of

Exclusion criteria

Exclusion criteria:

  • Treatment resistance as defined by treatment (ever) with clozapine
  • Dependence syndrome of alcohol or psychoactive substances other than cannabis (DF1X.2 other than DF12.2)
  • Psychotic disorder induced by alcohol or psychoactive substances other than cannabis (DF1X.5 other than DF12.5)
  • Treatment with a long-acting injectable antipsychotic within the past month (or corresponding to the usual interval between two injections)
  • Treatment with an oral antipsychotic within the past 7 days
  • Use of self-administered CBD products during the trial
  • Patients involuntarily admitted
  • Pregnancy or lactation
  • Severe physical illness that might influence the ability to comply with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cannabidiol

    Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks. AND Risperione placebo, encapsulated tablet.

    Drug: Cannabidiol

  • Active comparator
    Risperidone

    Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks AND Cannabidiol placebo, oral suspension

    Drug: Risperidone

Interventions

  • Cannabidiol oral suspension

    Also known as: Epidiolex

  • Risperidone, encapsulated tablet.

    Also known as: Risperidon

06

What researchers measure

Primary outcomes

  1. Psychotic symptoms

    Positive and Negative Syndrome Scale (PANSS) positive subscale, range 7-49. A measure of symptom severity. Higher values are worse.

    Time frame: 7 weeks follow-up

Secondary outcomes

  1. Cannabis cessation (no use of cannabis within the past two weeks) (for current cannabis users at baseline)

    Timeline follow back method

    Time frame: 7 weeks follow-up

  2. Cannabis use by self-reported days of cannabis use per week, since last study visit.

    Timeline follow back method

    Time frame: 7 weeks follow-up

  3. Amount of cannabis use per day, self-reported, since last study visit.

    PSYSCAN cannabis questionnaire# 6-8

    Time frame: 7 weeks follow-up

  4. Response

    Response defined by PANSS total 25 percentile changes

    Time frame: 7 weeks follow-up

  5. Remission

    Symptomatic remission is defined according to the Andreasen et al remission criteria. The criteria define symptomatic remission as a rating of no more than mild in four core positive and four core negative symptoms on the Positive and Negative Syndrome Scale (P1, P2 P3, N1, N4, N6, G5, G9,) that is sustained for ≥6 months. Because of the duration of this study, the requirement of 6 month will not be considered.

    Time frame: 7 weeks follow-up

  6. Global illness severity

    Global illness severity is assessed with the Clinical Global Impression Scale (CGI). We will use the severity (CGI-S) at baseline and improvement (CGI-I) scores of the CGI at the following visits. Response will be defined as much improved or better on the CGI-I. The main item 'severity of illness' is measured on a 7-point Likert scale (from 1 'normal, not at all ill' to 7 'among the most extremely ill patients').

    Time frame: 7 weeks follow-up

  7. Psychosocial functioning

    Personal and Social Performance Scale (PSP). Higher is better, range 1-100.

    Time frame: 7 weeks follow-up

  8. Neurocognitive functioning

    Brief Assessment of Cognition in Schizophrenia (BACS). Neurocognitive Test Battery. One composite score and six subscales.

    Time frame: 7 weeks follow-up

  9. Subjective well-being

    Subjective Well-being under Neuroleptics Scale (SWN). A measure of health-related quality of life.

    Time frame: 7 weeks follow-up

  10. Circadian rest-activity cycle

    Actigraphy. A wrist-worne device that measures kinetic energy.

    Time frame: 7 weeks follow-up

  11. Subjective sleep quality

    Pittsburgh Sleep Quality Index (PSQI). One total score, seven subscales.

    Time frame: 7 weeks follow-up

  12. Objective sleep evaluation

    Polysomnography (PSG). A measure of objective sleep variables

    Time frame: 7 weeks follow-up

  13. Metabolomics

    Markers for cannabinoids, dopamine and serotonin and their precursors and metabolites in the blood

    Time frame: 7 weeks follow-up

Other outcomes

  1. Adverse events (AEs), discontinuation due to AEs, and serious adverse events (SAEs)

    Self-report

    Time frame: From baseline to 2 weeks after end of treatment

  2. Extrapyramidal and other side effects

    Udvalget for Kliniske Undersoegelser (UKU) short version A clinician-rated scale to assess antipsychotic side effects

    Time frame: 7 weeks follow-up

07

Study locations

1 site
  • Center for Neuropsychiatric Schizophrenia Research
    Glostrup Municipality, 2600, Denmark
08

References and documents

Publications

  • Rasmussen JO, Jennum P, Linnet K, Glenthoj BY, Baandrup L. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. BMC Psychiatry. 2021 Aug 14;21(1):404. doi: 10.1186/s12888-021-03395-9. PubMed 34391393 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data will be available. In addition, the study protocol will be available. Data will be available after publication of planned primary and secondary analyses. There will be no end date for availability of data. Individual participant data will be available for meta-analysis. Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.

Time frame: Data will be available after publication of planned primary and secondary analyses. No end date.

Access criteria: Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Nov 2025, 53 months.

Of 28 non-industry phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 53. This study's 53 months is close to that.

Counting every sponsor, half of 39 studies reached it within 39 months; a quarter within 22 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2019
First posted
Sep 26, 2019
StartActual
Jun 1, 2021
Primary completionActual
Nov 25, 2025
CompletionEst.
Mar 31, 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04105231
Lead sponsor
Lone Baandrup
Collaborators
Danish Center for Sleep Medicine, Copenhagen University Hospital, Denmark, Glostrup University Hospital, Copenhagen, University of Copenhagen
Responsible party
Lone Baandrup (Head of Clinic, University of Copenhagen) — Sponsor-investigator
First posted
Sep 26, 2019
Start date
Jun 1, 2021
Primary completion
Nov 25, 2025
Completion
Mar 31, 2026 (estimated)
Last update
Jan 27, 2026

Study contacts

Lone Baandrup, MD, PhD
principal investigator · Mental Health Services Capital Region in Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion